home Search results for 'Adagrasib'
Apparatus

Two-Drug Combination For Specific Mutation Colorectal Cancer With 100% Efficiency!

A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.

Apparatus

World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!

The FDA has granted accelerated approval to Adagrasib for the treatment of patients with KRAS G12C mutations in non-small cell lung cancer. In the trial, the drug resulted in disease control in 80% of patients, of which, 43% had substantial tumour shrinkage.